Loading...
Header Logo
Keywords
Last Name
Institution

Gary E Raskob

TitleDean
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPublic Health Office of Dean
Address801 NE 13th St
Oklahoma City OK 73104-5005
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    P50HL054502     (MCEVER, RODGER PAUL)Mar 1, 1996 - Jan 31, 2006
    NIH/NHLBI
    THROMBOSIS: ETIOLOGY, RISK FACTORS AND TREATMENT
    Role: Co-Principal Investigator

    S07RR018224     (RASKOB, GARY E.)Sep 1, 2002 - Aug 31, 2006
    NIH/NCRR
    OU Human Research Protection Program, Year 2
    Role: Principal Investigator

    R49CE000788     (RASKOB, GARY E.)Aug 1, 2005 - Jul 31, 2007
    CDC/NCIPC
    OU Developmental Center for Injury Prevention Research
    Role: Principal Investigator

    U50DD000899     (RASKOB, GARY E.)Apr 1, 2012 - Mar 31, 2015
    CDC/NCBDD
    ACTIVE SURVEILLANCE FOR VENOUS THROMBOEMBOLISM IN A RACIALLY DIVERSE POPULATION
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 Jun 22; 117(9). PMID: 28640324.
      View in: PubMed
    2. Blumenthal DS, Raskob G. The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. Am J Prev Med. 2017 Mar; 52(3S3):S214-S215. PMID: 28215366.
      View in: PubMed
    3. Di Nisio M, Raskob G, Büller HR, Grosso MA, Zhang G, Winters SM, Cohen A. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 Apr 03; 117(4):784-793. PMID: 28151543.
      View in: PubMed
    4. Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 Jan 26; 117(2):415-421. PMID: 27853808.
      View in: PubMed
    5. Bleker SM, Cohen AT, Büller HR, Agnelli G, Gallus AS, Raskob GE, Weitz JI, Curto M, Sisson M, Middeldorp S. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164. PMID: 27583312.
      View in: PubMed
    6. Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45. PMID: 27570090.
      View in: PubMed
    7. Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53. PMID: 27440518.
      View in: PubMed
    8. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87. PMID: 27476789.
      View in: PubMed
    9. Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 Jul 01; 76(13):3671-5. PMID: 27527638.
      View in: PubMed
    10. Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AW. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068. PMID: 27262225.
      View in: PubMed
    11. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29; 118(9):1340-7. PMID: 27126645.
      View in: PubMed
    12. Aelion CM, Airhihenbuwa CO, Alemagno S, Amler RW, Arnett DK, Balas A, Bertozzi S, Blakely CH, Boerwinkle E, Brandt-Rauf P, Buekens PM, Chandler GT, Chang RW, Clark JE, Cleary PD, Curran JW, Curry SJ, Diez Roux AV, Dittus R, Ellerbeck EF, El-Mohandes A, Eriksen MP, Erwin PC, Evans G, Finnegan JR, Fried LP, Frumkin H, Galea S, Goff DC, Goldman LR, Guilarte TR, Rivera-Gutiérrez R, Halverson PK, Hand GA, Harris CM, Healton CG, Hennig N, Heymann J, Hunter D, Hwang W, Jones RM, Klag MJ, Klesges LM, Lahey T, Lawlor EF, Maddock J, Martin WJ, Mazzaschi AJ, Michael M, Mohammed SD, Nasca PC, Nash D, Ogunseitan OA, Perez RA, Perri M, Petersen DJ, Peterson DV, Philbert M, Pinto-Martin J, Raczynski JM, Raskob GE, Rimer BK, Rohrbach LA, Rudkin LL, Siminoff L, Szapocznik J, Thombs D, Torabi MR, Weiler RM, Wetle TF, Williams PL, Wykoff R, Ying J. The US Cancer Moonshot initiative. Lancet Oncol. 2016 May; 17(5):e178-80. PMID: 27301041.
      View in: PubMed
    13. Liles NW, Page EE, Liles AL, Vesely SK, Raskob GE, George JN. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol. 2016 May; 91(5):461-6. PMID: 26822544.
      View in: PubMed
    14. Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 Jul 04; 116(1):155-61. PMID: 27010092.
      View in: PubMed
    15. Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, Meyer G, Verhamme P, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36. PMID: 27132697.
      View in: PubMed
    16. Raskob G, Wendelboe AM. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 May; 14(5):1111-2. PMID: 26866426.
      View in: PubMed
    17. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 Jun 02; 115(6):1240-8. PMID: 26842902.
      View in: PubMed
    18. Raskob GE, Gallus AS, Sanders P, Thompson JR, Agnelli G, Buller HR, Cohen AT, Ramacciotti E, Weitz JI. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16. PMID: 26661288.
      View in: PubMed
    19. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10. PMID: 26654719; PMCID: PMC4706477 [Available on 01/01/17].
    20. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91. PMID: 26407753.
      View in: PubMed
    21. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76. PMID: 26271200.
      View in: PubMed
    22. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71. PMID: 26084415.
      View in: PubMed
    23. Wendelboe AM, Campbell J, McCumber M, Bratzler D, Ding K, Beckman M, Reyes N, Raskob G. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18. PMID: 26385027; PMCID: PMC4598067.
    24. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40. PMID: 25482425; PMCID: PMC4367537.
    25. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25473673.
      View in: PubMed
    26. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25319500.
      View in: PubMed
    27. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71. PMID: 25304324.
      View in: PubMed
    28. Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014 Oct; 40(7):724-35. PMID: 25302681.
      View in: PubMed
    29. Raskob GE. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2. PMID: 25606628.
      View in: PubMed
    30. Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30. PMID: 24597472.
      View in: PubMed
    31. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20; 11(1):21. PMID: 24053656; PMCID: PMC3850944.
    32. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15. PMID: 23991658.
      View in: PubMed
    33. Raskob GE. Importance of subsegmental pulmonary embolism. Blood. 2013 Aug 15; 122(7):1094-5. PMID: 23950170.
      View in: PubMed
    34. Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94. PMID: 23574579.
      View in: PubMed
    35. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808. PMID: 23808982.
      View in: PubMed
    36. Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini JA, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen MR, Lowe GD, Markel A, Prandoni P, Raskob G, Spyropoulos AC, Turpie AG, Walenga JM, Warwick D. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260. PMID: 24402349.
      View in: PubMed
    37. Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, Lassen MR, Wang L. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51. PMID: 23279103.
      View in: PubMed
    38. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708. PMID: 23216615.
      View in: PubMed
    39. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 05; 366(14):1287-97. PMID: 22449293.
      View in: PubMed
    40. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64. PMID: 22323697.
      View in: PubMed
    41. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb 11; 379(9815):537-46. PMID: 22240409; PMCID: PMC3426911.
    42. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9. PMID: 22130488.
      View in: PubMed
    43. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036. PMID: 21610040; PMCID: PMC3100759.
    44. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98. PMID: 21175312.
      View in: PubMed
    45. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510. PMID: 21128814.
      View in: PubMed
    46. Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7. PMID: 20886185.
      View in: PubMed
    47. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9. PMID: 20589317.
      View in: PubMed
    48. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. PMID: 20558556.
      View in: PubMed
    49. van Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M, Piovella F, Prins MH, Raskob GE, Büller HR. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91. PMID: 20508907.
      View in: PubMed
    50. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9. PMID: 20331950.
      View in: PubMed
    51. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15. PMID: 20206776.
      View in: PubMed
    52. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. PMID: 19837821.
      View in: PubMed
    53. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604. PMID: 19657123.
      View in: PubMed
    54. Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S, Poon MC, Raskob G. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3. PMID: 19635277.
      View in: PubMed
    55. Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30. PMID: 19348685; PMCID: PMC2686675.
    56. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9. PMID: 19350123.
      View in: PubMed
    57. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. PMID: 18674477.
      View in: PubMed
    58. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7. PMID: 18621928.
      View in: PubMed
    59. Stein PD, Sostman HD, Bounameaux H, Buller HR, Chenevert TL, Dalen JE, Goodman LR, Gottschalk A, Hull RD, Leeper KV, Pistolesi M, Raskob GE, Wells PS, Woodard PK. Challenges in the diagnosis of acute pulmonary embolism. Am J Med. 2008 Jul; 121(7):565-71. PMID: 18589050.
      View in: PubMed
    60. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S. PMID: 18574272.
      View in: PubMed
    61. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9. PMID: 18534438.
      View in: PubMed
    62. Rathbun SW, Whitsett TL, Raskob GE. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800. PMID: 17982322.
      View in: PubMed
    63. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505. PMID: 17968019.
      View in: PubMed
    64. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13. PMID: 17904462.
      View in: PubMed
    65. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104. PMID: 17855670.
      View in: PubMed
    66. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12. PMID: 17855671.
      View in: PubMed
    67. Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4. PMID: 17403087.
      View in: PubMed
    68. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82. PMID: 17208082.
      View in: PubMed
    69. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72. PMID: 17145251.
      View in: PubMed
    70. Miller A, Campbell I, Fennerty T, Raskob GE, Büller HR. Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300. PMID: 16840417.
      View in: PubMed
    71. Hemenway D, Aglipay GS, Helsing KL, Raskob GE. Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51. PMID: 16640161; PMCID: PMC1525291.
    72. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81. PMID: 16424429.
      View in: PubMed
    73. Rathbun SW, Whitsett TL, Raskob GE. Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med. 2004 Dec 07; 141(11):839-45. PMID: 15583225; PMCID: PMC1382279.
    74. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S. PMID: 15383476.
      View in: PubMed
    75. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S. PMID: 15383479.
      View in: PubMed
    76. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73. PMID: 15172900.
      View in: PubMed
    77. Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5. PMID: 15006941; PMCID: PMC1215466.
    78. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20. PMID: 15209529.
      View in: PubMed
    79. Henderson JN, Henderson LC, Raskob GE, Boatright DT. Chemical (VX) terrorist threat: public knowledge, attitudes, and responses. Biosecur Bioterror. 2004; 2(3):224-8. PMID: 15588061.
      View in: PubMed
    80. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S. PMID: 14668421.
      View in: PubMed
    81. Davidson BL, Sullivan SD, Kahn SR, Borris L, Bossuyt P, Raskob G. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S. PMID: 14668423.
      View in: PubMed
    82. George JN, Raskob GE, Vesely SK, Moore D, Lyons RM, Cobos E, Towell BL, Klug P, Guthrie TH. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9. PMID: 14587042.
      View in: PubMed
    83. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702. PMID: 14585937.
      View in: PubMed
    84. Blevins S, Edwards S, Raskob G. Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients. Curr Opin Hematol. 2003 Sep; 10(5):345-50. PMID: 12913788.
      View in: PubMed
    85. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8. PMID: 12637323.
      View in: PubMed
    86. Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96. PMID: 12696988.
      View in: PubMed
    87. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4. PMID: 11863471.
      View in: PubMed
    88. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69. PMID: 11712876.
      View in: PubMed
    89. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyák K, Francis CW, Marder VJ, Raskob GE. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60. PMID: 11525697.
      View in: PubMed
    90. Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van Der Meer J, Piovella F, Raskob G, Gent M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8. PMID: 11435341.
      View in: PubMed
    91. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S. PMID: 11157645.
      View in: PubMed
    92. Stein PD, Hull RD, Raskob GE. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6. PMID: 10996581.
      View in: PubMed
    93. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, Tytle TL, Owen WL, McKee PA. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13. PMID: 10668832.
      View in: PubMed
    94. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 Feb 01; 132(3):227-32. PMID: 10651604.
      View in: PubMed
    95. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36. PMID: 10647762.
      View in: PubMed
    96. Vesely S, Buchanan GR, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol. 2000 Jan-Feb; 22(1):55-61. PMID: 10695823.
      View in: PubMed
    97. Raskob GE, Hull RD. Diagnosis of pulmonary embolism. Curr Opin Hematol. 1999 Sep; 6(5):280-4. PMID: 10468141.
      View in: PubMed
    98. Rizvi MA, Shah SR, Raskob GE, George JN. Drug-induced thrombocytopenia. Curr Opin Hematol. 1999 Sep; 6(5):349-53. PMID: 10468152.
      View in: PubMed
    99. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, Hull RD, Hyers TM, Leeper KV, Morris TA, Moser KM, Raskob GE, Shure D, Sostman HD, Taylor Thompson B. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999 Sep; 160(3):1043-66. PMID: 10471639.
      View in: PubMed
    100. George JN, Woolf SH, Raskob GE. The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications. Blood. 1999 Sep 01; 94(5):1515-6. PMID: 10477675.
      View in: PubMed
    101. Raskob GE. Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Curr Opin Pulm Med. 1999 Jul; 5(4):216-21. PMID: 10407690.
      View in: PubMed
    102. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 Jan 25; 159(2):137-41. PMID: 9927095.
      View in: PubMed
    103. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998 Dec 01; 129(11):886-90. PMID: 9867731.
      View in: PubMed
    104. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S. PMID: 9822060.
      View in: PubMed
    105. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12. PMID: 9759687.
      View in: PubMed
    106. Hull RD, Pineo GF, Raskob GE. Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med. 1998 Sep; 132(3):171-4. PMID: 9735921.
      View in: PubMed
    107. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci. 1998 Aug; 316(2):87-93. PMID: 9704662.
      View in: PubMed
    108. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998 Apr; 21(2):71-8. PMID: 9562927.
      View in: PubMed
    109. George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998 Feb; 30(1):38-44. PMID: 9556088.
      View in: PubMed
    110. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16. PMID: 10069757.
      View in: PubMed
    111. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, Tytle TL, McKee PA. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7. PMID: 9424975.
      View in: PubMed
    112. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol. 1998 Jan; 35(1 Suppl 1):5-8. PMID: 9523743.
      View in: PubMed
    113. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8. PMID: 9531224.
      View in: PubMed
    114. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21. PMID: 9361572.
      View in: PubMed
    115. Raskob GE, George JN. Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41. PMID: 9382408.
      View in: PubMed
    116. George JN, Raskob GE. Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim. PMID: 9307602.
      View in: PubMed
    117. Raskob GE. Duration of anticoagulant treatment for venous thrombosis. Curr Opin Pulm Med. 1997 Jul; 3(4):286-90. PMID: 9262115.
      View in: PubMed
    118. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, Trowbridge AA, Elliott CG, Green D, Feinglass J. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94. PMID: 9040295.
      View in: PubMed
    119. Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303. PMID: 9040296.
      View in: PubMed
    120. Raskob GE, Durica SS, Owen WL, Comp PC. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6. PMID: 8916497.
      View in: PubMed
    121. Raskob GE. Oral anticoagulant therapy. Curr Opin Hematol. 1996 Sep; 3(5):361-4. PMID: 9372102.
      View in: PubMed
    122. Henry JW, Stein PD, Gottschalk A, Raskob GE. Pulmonary embolism among patients with a nearly normal ventilation/perfusion lung scan. Chest. 1996 Aug; 110(2):395-8. PMID: 8697840.
      View in: PubMed
    123. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 01; 88(1):3-40. PMID: 8704187.
      View in: PubMed
    124. Raskob GE. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10. PMID: 9363157.
      View in: PubMed
    125. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60. PMID: 8774204.
      View in: PubMed
    126. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S. PMID: 7555182.
      View in: PubMed
    127. Hull RD, Raskob GE, Pineo GF, Brant RF. The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51. PMID: 7677550.
      View in: PubMed
    128. Raskob GE. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9. PMID: 9372022.
      View in: PubMed
    129. Raskob GE. Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7. PMID: 9363067.
      View in: PubMed
    130. Hull RD, Feldstein W, Pineo GF, Raskob GE. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96. PMID: 8578456.
      View in: PubMed
    131. Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9. PMID: 7756639.
      View in: PubMed
    132. Raskob GE, Hull RD, Pineo GF. Impedance plethysmography for suspected deep-vein thrombosis. Arch Intern Med. 1995 Apr 10; 155(7):773, 776. PMID: 7695467.
      View in: PubMed
    133. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994 Nov 03; 331(18):1207-11. PMID: 7935660.
      View in: PubMed
    134. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61. PMID: 7942522.
      View in: PubMed
    135. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med. 1994 Sep 01; 121(5):313-7. PMID: 8042819.
      View in: PubMed
    136. Raskob GE, Durica SS. Treatment of venous thromboembolism. Curr Opin Hematol. 1994 Sep; 1(5):329-35. PMID: 9371301.
      View in: PubMed
    137. Raskob GE, Comp PC. Preventing systemic embolism in patients with abnormal ventricular function. Cardiol Clin. 1994 Aug; 12(3):477-85. PMID: 7805080.
      View in: PubMed
    138. Elliott CG, Hiltunen SJ, Suchyta M, Hull RD, Raskob GE, Pineo GF, Jensen RL, Yeates S, Kitterman N. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004. PMID: 8179457.
      View in: PubMed
    139. Hull RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G, Pineo GF. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97. PMID: 8297195.
      View in: PubMed
    140. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6. PMID: 8413432.
      View in: PubMed
    141. Raskob GE, Pineo GF, Hull RD. Impedance plethysmography and DVT diagnosis. Ann Intern Med. 1993 Aug 01; 119(3):247. PMID: 8323097.
      View in: PubMed
    142. Raskob GE. Long-term oral anticoagulant therapy for coronary artery disease. Haemostasis. 1993 Mar; 23 Suppl 1:32-41. PMID: 8495870.
      View in: PubMed
    143. Elliott CG, Suchyta M, Rose SC, Talbot S, Ford C, Raskob G, Hull R, Davidson B. Duplex ultrasonography for the detection of deep vein thrombi after total hip or knee arthroplasty. Angiology. 1993 Jan; 44(1):26-33. PMID: 8424582.
      View in: PubMed
    144. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S. PMID: 1395820.
      View in: PubMed
    145. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95. PMID: 1497392.
      View in: PubMed
    146. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82. PMID: 1545850.
      View in: PubMed
    147. Hull RD, Raskob GE. Venous thromboembolic disease. Curr Opin Cardiol. 1991 Oct; 6(5):750-6. PMID: 10150065.
      View in: PubMed
    148. Hull RD, Raskob GE. Low-probability lung scan findings: a need for change. Ann Intern Med. 1991 Jan 15; 114(2):142-3. PMID: 1984390.
      View in: PubMed
    149. Raskob GE, Hull RD. Diagnosis and management of pulmonary thromboembolism. Q J Med. 1990 Aug; 76(280):787-97. PMID: 2217683.
      View in: PubMed
    150. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4. PMID: 2183055.
      View in: PubMed
    151. Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC, Dale NI, Reed-Davis R, Lofthouse RN, Anderson C. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990 May 02; 263(17):2313-7. PMID: 2182917.
      View in: PubMed
    152. Hull RD, Raskob GE, Carter CJ. Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med. 1990 May 01; 112(9):663-7. PMID: 2334080.
      View in: PubMed
    153. Farrow L, Mungall D, Raskob G, Hull R. Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9. PMID: 2349607.
      View in: PubMed
    154. Hull RD, Raskob GE, Coates G, Panju AA. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6. PMID: 2295242.
      View in: PubMed
    155. Hull RD, Raskob GE, Coates G, Panju AA, Gill GJ. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989 Nov; 149(11):2549-55. PMID: 2818113.
      View in: PubMed
    156. Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900. PMID: 2592581.
      View in: PubMed
    157. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989 Feb; 95(2 Suppl):26S-36S. PMID: 2644101.
      View in: PubMed
    158. Fuller H, Raskob G, ter Keurs H, Hull R. The current status and future directions of impedance cardiography in ICU. Ann Biomed Eng. 1989; 17(5):483-94. PMID: 2610420.
      View in: PubMed
    159. Raskob GE, Carter CJ, Hull RD. Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27. PMID: 2643814.
      View in: PubMed
    160. Raskob GE, Carter CJ, Hull RD. Heparin therapy for venous thrombosis and pulmonary embolism. Blood Rev. 1988 Dec; 2(4):251-8. PMID: 3061531.
      View in: PubMed
    161. Hull RD, Raskob GE, Carter CJ, Coates G, Gill GJ, Sackett DL, Hirsh J, Thompson M. Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44. PMID: 3355304.
      View in: PubMed
    162. Hull RD, Raskob GE. Frequency of a normal lung scan observed in the urokinase-streptokinase pulmonary embolism trial. Invest Radiol. 1987 Apr; 22(4):357. PMID: 3583658.
      View in: PubMed
    163. Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):104B-113B. PMID: 3537063.
      View in: PubMed
    164. Hirsh J, Hull RD, Raskob GE. Clinical features and diagnosis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):114B-127B. PMID: 3537064.
      View in: PubMed
    165. Hirsh J, Hull RD, Raskob GE. Diagnosis of pulmonary embolism. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):128B-136B. PMID: 3537065.
      View in: PubMed
    166. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30; 315(18):1109-14. PMID: 3531862.
      View in: PubMed
    167. Hull RD, Raskob GE, Hirsh J. The diagnosis of clinically suspected pulmonary embolism. Practical approaches. Chest. 1986 May; 89(5 Suppl):417S-425S. PMID: 3698720.
      View in: PubMed
    168. Hull RD, Raskob GE, Hirsh J. Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S. PMID: 2421985.
      View in: PubMed
    169. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1986 Feb; 89(2 Suppl):16S-25S. PMID: 3510826.
      View in: PubMed
    170. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986 Jan; 68(1):146-50. PMID: 2416763.
      View in: PubMed
    171. Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985 Dec; 88(6):819-28. PMID: 4064769.
      View in: PubMed
    172. Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60. PMID: 3905338.
      View in: PubMed
    173. Raskob GE, Lofthouse RN, Hull RD. Methodological guidelines for clinical trials evaluating new therapeutic approaches in bone and joint surgery. J Bone Joint Surg Am. 1985 Oct; 67(8):1294-7. PMID: 4055857.
      View in: PubMed
    174. Hull RD, Raskob GE, LeClerc JR, Jay RM, Hirsh J. The diagnosis of clinically suspected venous thrombosis. Clin Chest Med. 1984 Sep; 5(3):439-56. PMID: 6435945.
      View in: PubMed
    175. Hull RD, Raskob GE, Hirsh J, Sackett DL. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9. PMID: 6427492.
      View in: PubMed
    176. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983 Jun; 98(6):891-9. PMID: 6859705.
      View in: PubMed
    177. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81. PMID: 6755255.
      View in: PubMed
    178. Raskob G, Jay R, Hull R. Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289. PMID: 7069699; PMCID: PMC1437633.
    Raskob's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _